Dr. Hawkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
86 Jonathan Lucas Street
Ho321s
Charleston, SC 29425Phone+1 843-876-4420
Summary
- Dr. William Hawkins is a surgical oncologist in Charleston, SC. He serves as the Deputy Director of the Hollings Cancer Center and focuses his leadership efforts on growth of translational science. He received his medical degree from Stony Brook University School of Medicine and has been in practice 20 years. Clinically he specializes in hepatobiliary surgery, pancreas, and surgical oncology (other than breast) and is experienced in cholangiocarcinoma, minimally invasive surgery, surgical oncology, pancreatectomy, and adenocarcinoma.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Complex General Surgical Oncology, 2002 - 2004
- Massachusetts General HospitalResidency, Surgery, 2000 - 2002
- Memorial Sloan Kettering Cancer CenterPost-Doctoral Fellowship, 1998 - 2000
- Stony Brook University Health Sciences Center School of MedicineClass of 1995
- State University of New York at Stony BrookBS, Biology, Magna Cum Laude, 1987 - 1991
Certifications & Licensure
- IL State Medical License 2021 - 2026
- SC State Medical License 2023 - 2025
- MO State Medical License 2004 - 2024
- NY State Medical License 1998 - 2005
- American Board of Surgery Surgery
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012
- Light up the night with hope award PanCAN, 2008
- Mentored Research Scholar American Cancer Society, 2008
- Join now to see all
Clinical Trials
- Registry Study - Whipple at the Splenic Artery Start of enrollment: 2010 Sep 20
- Reinforced Staple Line on Leak Rate in Distal Pancreatectomy Start of enrollment: 2007 Jun 01
- FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma Start of enrollment: 2012 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- Plasma Ceramide C24:0/C16:0 Ratio is Associated with Improved Survival in Patients with Pancreatic Ductal Adenocarcinoma.Joshua D Mitchell, Usman Panni, Nicole Fergestrom, Adetunji T Toriola, Timothy M Nywening
Annals of Surgical Oncology. 2024-12-01 - Cytotoxic sigma-2 ligands trigger cancer cell death via cholesterol-induced-ER-stress.Rony Takchi, Bethany C Prudner, Qingqing Gong, Takaomi Hagi, Kenneth F Newcomer
Cell Death & Disease. 2024-05-02 - 2 citationsNeoadjuvant Chemotherapy is Associated with Increased Risk of Postoperative DVT After Distal Pancreatectomy for Pancreatic Adenocarcinoma: a NSQIP Analysis.Keenan J Robbins, Kenneth F Newcomer Jr, Erica K Barnell, Michael A Anzelmo, Jingxia Liu
Annals of Surgical Oncology. 2024-05-01
Journal Articles
- Post-Discharge Phone Call Intervention After PancreaticoduodenectomyDarren R Cullinan, Chet Hammill, Ryan C Fields, Steven M Strasberg, William G Hawkins, Journal of The American College of Surgeons
- Intensity Modulated Radiation Therapy and Surgery for Management of Retroperitoneal Sarcomas: A Single-Institution ExperienceTodd DeWees, Imran Zoberi, Jeffrey Olsen, Jeff Michalski, William Hawkins, BioMed Central
- Variations in Definition and Method of Retrieval of Complications Influence Outcomes Statistics after Pancreatoduodenectomy: Comparison of NSQIP with Non-NSQIP MethodsSanford DE, Woolsey CA, Hall BL, Linehan DC, Hawkins WG, Fields RC, Strasberg SM, J Am Coll Surg, 9/1/2014
- Join now to see all
Books/Book Chapters
Authored Content
- Post-Discharge Phone Call Intervention After PancreaticoduodenectomyOctober 2018
Press Mentions
- Immune-Boosting Compound Makes Immunotherapy Effective Against Pancreatic CancerJuly 17th, 2019
- Immune-Boosting Compound Makes Immunotherapy Effective Against Pancreatic CancerJuly 3rd, 2019
- $10.4 Million Awarded for Pancreatic Cancer ResearchAugust 15th, 2016
- Join now to see all
Grant Support
- On The Trail To Pancreas Cancer-Selective Tumor Cell Death (APOPTOSIS)National Cancer Institute2010–2011
- Small Fish To Evaluate Toxic ChemicalsNational Institute Of Environmental Health Sciences1994
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: